A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 07 Apr 2017 Planned end date changed from 1 Aug 2018 to 1 Sep 2018
- 07 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017.
- 04 Oct 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.